Clinical Research for Gemcitabine Combined with Fluorouracil in the Treatment of Advanced Ovarian Cancer Patients with Taxane and Cisplatin Resistance

狄剑士,刘欣,王俊,毕经旺

DOI: https://doi.org/10.3969/j.issn.1671-4008.2012.12.004

2012-01-01

Abstract:Objective To observe the efficacy and adverse reaction of gemcitabine combined with fluorouracil in the treatment of advanced ovarian cancer patients with taxane and cisplatin resistance.Methods Thirty-six patients who had failures to or relapse after previous treatment were given with taxane and cisplatin as the following regimen: Gemcitabine was administered by intravenous drip at a dose of 1000 mg/m2(on day 1 and day 8),while fluorouracil and calcium folinate were 300 mg/m2(from the first day to the third day) and 200 mg/m2(from the 1st to 3rd day),respectively.Fluorouracil was continuous given intravenously with micro-pumped at 1500 mg/m2 for 72 hours.Results All 36 patients were qualified for efficacy analysis,complete response(CR) was observed in 7 patients(19.4%) and partial response(PR) in 12 patients(33.3%),with an overall response rate of 52.8%;7 cases achieved steady disease(SD) and 10 cases got progression of disease(PD).The rate of grade Ⅲ-Ⅳ haematological adverse reactions was 27.2%,with neutropenia 21.3%,thrombocytopenia 12.5% and anemia 10.3%.In addition,the gastrointestinal tract reaction(30.9%),oral ulcer(27.2%) and chemotherapy enteritis(16.9%) all were the common toxicities.Conclusion Gemcitabine combined with fluorouracil for patients with advanced ovarian cancer who are of resistance to taxane and cisplatin is effective and well tolerated.